Abstract
AbstractBackgroundSarcopenia is the progressive generalized loss of skeletal muscle mass, strength, and function that occurs with aging. This study was undertaken to identify new biomarkers of sarcopenia by proteomics analysis of female sera.MethodsA case–control study was set up, for which 19 sarcopenic subjects and 20 control subjects, according to the European Working Group on Sarcopenia Older People criteria published in 2010 (EWGSOP1), were enrolled. All the subjects were at least 65 years old and in majority female. Biomarker screening was performed by a comparative mass spectrometry analysis. Protein expression levels between the two groups were compared. One of the identified biomarkers, cathepsin D, was measured by immunoassay on the serum of the full sample set (n = 39). Its diagnostic performance was evaluated with a receiver operating characteristic curve (ROC curve).ResultsTwo biomarkers were identified: fructose‐biphosphate aldolase A (P ≤ 0.05) and cathepsin D (P ≤ 0.05). The levels of all of them were higher in sarcopenic patients. It was confirmed by immunoassay that cathepsin D levels in serum were significantly higher in the sarcopenic group of patients (P = 0.038). An inverse correlation (−0.385) was observed between cathepsin D levels in serum and gait speed. The area under the ROC curve measurement (AUC = 0.696) demonstrated that cathepsin D levels could discriminate between sarcopenic and non‐sarcopenic subjects. A predictive model including cathepsin D, age, and body mass index was established to improve the diagnostic performance (AUC = 0.908).ConclusionsCathepsin D has been identified as a diagnostic biomarker of sarcopenia.
Highlights
Sarcopenia is a disease of the elderly, whose physiopathological mechanisms are still poorly understood
EWGSOP1 definition implies that sarcopenic patients (S3, Table 1) had a low handgrip strength (
Patients were enrolled in a case–control study and allocated to the control group or to the sarcopenic group, depending on their characteristics and to the main sarcopenia definition published in 2010 by a group of experts in the field
Summary
Sarcopenia is a disease of the elderly, whose physiopathological mechanisms are still poorly understood. Sarcopenia is associated with poor quality of life,[1] an increased risk of dependence, and mortality.[2] Prevalence of sarcopenia correspond to about 5–10% of persons over 65 It increases with age and can be over 50% for persons above 80 years old.[3] Prevalence estimation depends on definition of sarcopenia considered.[4]. One of the identified biomarkers, cathepsin D, was measured by immunoassay on the serum of the full sample set (n = 39). It was confirmed by immunoassay that cathepsin D levels in serum were significantly higher in the sarcopenic group of patients (P = 0.038). The area under the ROC curve measurement (AUC = 0.696) demonstrated that cathepsin D levels could discriminate between sarcopenic and non‐sarcopenic subjects. Conclusions Cathepsin D has been identified as a diagnostic biomarker of sarcopenia
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
